Barclays
CRDL icon

Barclays’s Cardiol Therapeutics CRDL Stock Holding History

Barclays’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-300
Closed -$318 – 5457
2026
Q2 		$318 Buy
300
+100
+50% +$127 ﹤0.01% 5060
2026
Q1 		$270 Buy
+200
New +$205 ﹤0.01% 4943

Other funds holding CRDL

Integrity Alliance
Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return
PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
MGO One Seven
MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return
Marble Harbor Investment Counsel
Marble Harbor Investment Counsel Boston, Massachusetts $1.02B AUM 15.73% 1-Year Est. Return
Boyer Financial Services
Boyer Financial Services Newport Beach, California $125M AUM 9.98% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
BWG
Boomfish Wealth Group Alpharetta, Georgia $231M AUM 21.59% 1-Year Est. Return
APW
Aurora Private Wealth Rockaway, New Jersey $159M AUM 18.68% 1-Year Est. Return
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Barclays's CRDL Position: Q3 2026 in Review

Barclays sold out of Cardiol Therapeutics (CRDL) in Q3 2026, closing a stake of 300 shares — an estimated $318 sold.

Barclays first reported a position in CRDL in Q1 2026 and held it in 2 quarters. The position peaked at $318 in Q2 2026. 20 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

  • Barclays reported no remaining Cardiol Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 300 Cardiol Therapeutics shares in Q3 2026, an estimated $318.
  • Barclays first reported a position in Cardiol Therapeutics in Q1 2026 and held it in 2 quarters.
  • Barclays's Cardiol Therapeutics position peaked at $318 in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.